Inotuzumab ozogamicin

From WikiMD.org
Jump to navigation Jump to search

Inotuzumab ozogamicin (pronounced as i noe tooz' ue mab oh zoe ga mye' sin) is a type of antibody-drug conjugate used in the treatment of certain types of cancer, specifically acute lymphoblastic leukemia (ALL).

Etymology

The name "Inotuzumab ozogamicin" is derived from its components: "Inotuzumab" is the monoclonal antibody that targets the CD22 antigen on the surface of B cells, and "ozogamicin" is the cytotoxic agent that is linked to the antibody.

Usage

Inotuzumab ozogamicin is used to treat adults with relapsed or refractory B-cell precursor ALL. It works by binding to the CD22 antigen on B cells, which allows the cytotoxic agent to enter the cell and cause cell death.

Side Effects

Common side effects of Inotuzumab ozogamicin include fatigue, fever, nausea, headache, abdominal pain, and thrombocytopenia. Severe side effects can include liver toxicity, infusion reactions, and hemorrhage.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski